SUMMARY Twelve patients with systemic sclerosis according to American Rheumatiwsm Association criteria were treated with intravenous 5-fluorouracil. Significant subjective and objective improvement occurred initially in the skin and subsequently in the involved viscera and vasculature. These preliminary results suggest that 5-fluorouracil may be an effective treatment for systemic sclerosis.
disease varies; complete remission occurs infrequently. Organ-system involvement is responsible for significant morbidity and mortality. A cumulative survival of 65% at two years and 35% at seven years from disease onset has been reported in one study, whereas, in another, 20% of affected individuals were alive 10 years after disease onset.2 3 More than 50 drugs have been tried as treatment for this disease." These drugs included nonsteroidals, sex and adrenal corticosteroids, immunosuppressors, antifibrotics, and others. Most of these agents have proved to be non-efficacious, with the possible exception of D-penicillamine, which may produce skin improvement and halt the progression of visceral involvement. These changes are relatively slow to appear, however, and the drug has definite and important side effects.4 7 The observations by one of us (CPS) of the efficacy of topically applied 5-fluorouracil in the treatment of a patient with plantar fibrosclerosis, and of improvement of skin manifestations in another patient with scleroderma after treatment with combination chemotherapy (methotrexate, Accepted for publication 13 April 1987. Correspondence to Dr Graciela S Alarc6n, 419B-SRC, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA. cyclophosphamide, and 5-FU) for breast cancer, prompted us to try this drug parenterally in one patient who presented with diffuse and rapidly progressive scieroderma. This patient responded dramatically to this treatment regimen and represents the first of the 12 cases presented in this report.
Patients and methods
The study was conducted in 12 patients with progressive systemic sclerosis (scleroderma) at the Arzobispo Loayza Hospital in Lima, Peru. All patients were female and either postmenopausal or using effective contraceptive methods at the time of the study. Written informed consent was obtained before participation.
Clinical evaluation was conducted by one of us (JAC) and included assessment of the skin and musculoskeletal systems as follows: (a) total skin score (TSS) as developed by Medsger et Table 1 for definitions of mild, moderate, and severe).
The patients were treated intravenously (IV) with 12-5 mg/kg/day of 5-FU for four to five doses, followed by four additional doses (8-10 mg/kg) given IV every two days (inductive phase). This was followed by a weekly dose of 10-20 mg/kg IV (maintenance dose). Therapy was monitored with a complete blood count and a clinical evaluation before each dose. While treated with 5-FU our patients did not receive other pharmacological agents, such as H2 blockers, corticosteroids, calcium channel blockers, and/or cytotoxics, which could have conceivably influenced the course of their illness.
Measurements performed at different times during the treatment were compared using nonparametric statistical tests. A p value 4 0-05 was chosen as indicative of statistical significance.
Results
The demographic and clinical characteristics (at baseline and last visit) of the 12 patients studied are listed in Table 2 . To better illustrate our report the course of the first three patients is presented here in some detail. Duration of treatment ranged from 1-5 to 20 months. Nine patients received 5-FU for at least six months.
PATIENT NO 1 A 28 year old woman presented with severe dysphagia, an 8 kg weight loss, Raynaud's phenomenon, diffuse scleroderma, and severe constipation (unresponsive to laxatives) of five months' duration. Shortly after initiating 5-FU she noticed decreased induration of her skin which was objectively shown by a decrease in the TSS (from 49 at baseline to 30 three months later). By the fourth month her constipation, dysphagia, and Raynaud's phenomenon had resolved. One year after initiating this treatment she discontinued the 5-FU for financial reasons. Her constipation recurred. She resumed treatment with 5-FU and has remained asymptomatic. She has regained weight and is receiving maintenance treatment with 5-FU as described.
PATIENT NO 2 A 24 year old woman presented with diffuse scleroderma of seven months' duration and significant pulmonary involvement characterised by progressive dyspnoea on exertion. She also had decreased range of motion (owing to skin group.bmj.com on June 22, 2017 -Published by http://ard.bmj.com/ Downloaded from at baseline; 22-0 at last visit; p=0-01), an increase in the oral opening (mean 31*3 mm at baseline; 33-5 at last visit; p=NS), and improvement in the flexion index (mean 98*5 mm at baseline; 92-6 at follow up; p=NS) and extension index (mean 140-1 mm at baseline; 146-4 at follow up; p=NS). By week [8] [9] [10] there was definite improvement of their Raynaud's phenomenon. The mean Raynaud's score was 2-2 at baseline compared with 1-3 at the last visit (p=0-035). Two patients had healing of digital ulcers. The mean oesophageal score was 1 6 at baseline compared with 0-8 at the last visit (p=0-07). The mean pulmonary score was 1-8 at baseline compared with 1 2 at the last visit (p=010). The mean functional index was 12-4 at baseline and 6 5 at the last visit (p=0-026). In general, the response appeared to be related to the severity of the disease and its duration, i.e., the worse the symptoms and the shorter the duration, the more beneficial the treatment.
Of the 487 doses that our 12 patients were supposed to receive, 77 were not administered; 12 doses could not be given owing to transient unavailability of 5-FU, and the remaining 65 owing to the patients' inability to come to the hospital. It should be noted that seven of the 12 patients continue to receive 5-FU. One patient died (patient No 3, described in detail: patient died of aspiration pneumonia), and the remaining four were lost to follow up 3, 6, 11, and 15 months after starting 5-FU (patients Nos 7, 9, 4 and 2 respectively). 5 
